VCA
RNAC icon

Verdence Capital Advisors’s Cartesian Therapeutics RNAC Stock Holding History

Verdence Capital Advisors’s Portfolio RNAC Stock Details RNAC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-567
Closed -$77K – 493
2021
Q1 		$77K Hold
567
– – 0.01% 429
2020
Q4 		$52K Buy
567
+34
+6% +$2.95K 0.01% 405
2020
Q3 		$40K Buy
+533
New +$40.8K 0.01% 364

Other funds holding RNAC

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
MWNA
Marshall Wace North America New York $23.5B AUM 46.46% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Verdence Capital Advisors's RNAC Position: Q2 2021 in Review

Verdence Capital Advisors sold out of Cartesian Therapeutics (RNAC) in Q2 2021, closing a stake of 567 shares — an estimated $77K sold.

Verdence Capital Advisors first reported a position in RNAC in Q3 2020 and held it in 3 quarters. The position peaked at $77K in Q1 2021. 101 funds tracked by Wall St. Rank hold RNAC as of Q2 2021.

  • Verdence Capital Advisors reported no remaining Cartesian Therapeutics position as of Q2 2021 after selling out during the quarter.
  • Verdence Capital Advisors sold 567 Cartesian Therapeutics shares in Q2 2021, an estimated $77K.
  • Verdence Capital Advisors first reported a position in Cartesian Therapeutics in Q3 2020 and held it in 3 quarters.
  • Verdence Capital Advisors's Cartesian Therapeutics position peaked at $77K in Q1 2021.
  • 101 funds tracked by Wall St. Rank held Cartesian Therapeutics as of Q2 2021.

Based on Verdence Capital Advisors's 13F filing for Q2 2021, filed 6 Aug 2021.